UA78029C2 - Fluorinated derivatives of 4-azasteroid as modulators of androgen receptor - Google Patents

Fluorinated derivatives of 4-azasteroid as modulators of androgen receptor Download PDF

Info

Publication number: UA78029C2
Authority: UA; Ukraine
Prior art keywords: fluoro; methyl; oxo; carboxamide; aza
Prior art date: 2002-03-13

Application number

UA20041008266A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Merck & Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-13

Filing date

2003-07-03

Publication date

2007-02-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28041817&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA78029(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-07-03 Application filed by Merck & Co Inc filed Critical Merck & Co Inc

2007-02-15 Publication of UA78029C2 publication Critical patent/UA78029C2/uk

Links

108010080146 androgen receptors Proteins 0.000 title claims abstract description 48
102000001307 androgen receptors Human genes 0.000 title abstract description 6
150000000520 4-azasteroids Chemical class 0.000 title description 8
150000001875 compounds Chemical class 0.000 claims abstract description 217
238000011282 treatment Methods 0.000 claims abstract description 82
210000000988 bone and bone Anatomy 0.000 claims abstract description 70
239000003098 androgen Substances 0.000 claims abstract description 50
208000001132 Osteoporosis Diseases 0.000 claims abstract description 44
210000002307 prostate Anatomy 0.000 claims abstract description 20
206010002261 Androgen deficiency Diseases 0.000 claims abstract description 16
206010060862 Prostate cancer Diseases 0.000 claims abstract description 15
208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 15
208000010392 Bone Fractures Diseases 0.000 claims abstract description 11
230000006378 damage Effects 0.000 claims abstract description 11
208000028169 periodontal disease Diseases 0.000 claims abstract description 11
208000008589 Obesity Diseases 0.000 claims abstract description 10
210000003205 muscle Anatomy 0.000 claims abstract description 10
235000020824 obesity Nutrition 0.000 claims abstract description 10
208000001076 sarcopenia Diseases 0.000 claims abstract description 10
208000032467 Aplastic anaemia Diseases 0.000 claims abstract description 9
206010006895 Cachexia Diseases 0.000 claims abstract description 9
201000003585 eunuchism Diseases 0.000 claims abstract description 9
208000018706 hematopoietic system disease Diseases 0.000 claims abstract description 9
208000037106 male hypogonadism Diseases 0.000 claims abstract description 9
201000001320 Atherosclerosis Diseases 0.000 claims abstract description 8
208000035150 Hypercholesterolemia Diseases 0.000 claims abstract description 7
208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 7
206010027304 Menopausal symptoms Diseases 0.000 claims abstract description 7
210000004291 uterus Anatomy 0.000 claims abstract description 7
201000006938 muscular dystrophy Diseases 0.000 claims abstract description 6
208000023275 Autoimmune disease Diseases 0.000 claims abstract description 5
208000036119 Frailty Diseases 0.000 claims abstract description 4
206010003549 asthenia Diseases 0.000 claims abstract description 4
208000002500 Primary Ovarian Insufficiency Diseases 0.000 claims abstract description 3
206010036601 premature menopause Diseases 0.000 claims abstract description 3
208000017942 premature ovarian failure 1 Diseases 0.000 claims abstract description 3
125000000217 alkyl group Chemical group 0.000 claims description 88
-1 (2) naphthyl Chemical group 0.000 claims description 71
238000000034 method Methods 0.000 claims description 51
150000003839 salts Chemical class 0.000 claims description 47
239000003112 inhibitor Substances 0.000 claims description 45
239000003795 chemical substances by application Substances 0.000 claims description 43
239000000203 mixture Substances 0.000 claims description 43
102100032187 Androgen receptor Human genes 0.000 claims description 42
229940088594 vitamin Drugs 0.000 claims description 38
239000011782 vitamin Substances 0.000 claims description 38
229940122361 Bisphosphonate Drugs 0.000 claims description 32
239000005557 antagonist Substances 0.000 claims description 30
229930003231 vitamin Natural products 0.000 claims description 30
235000013343 vitamin Nutrition 0.000 claims description 30
150000004663 bisphosphonates Chemical class 0.000 claims description 29
239000000262 estrogen Substances 0.000 claims description 29
229940011871 estrogen Drugs 0.000 claims description 29
150000003722 vitamin derivatives Chemical class 0.000 claims description 28
125000004432 carbon atom Chemical group C* 0.000 claims description 25
230000011164 ossification Effects 0.000 claims description 24
125000003118 aryl group Chemical group 0.000 claims description 23
125000001424 substituent group Chemical group 0.000 claims description 20
239000000199 parathyroid hormone Substances 0.000 claims description 18
102000003982 Parathyroid hormone Human genes 0.000 claims description 17
108090000445 Parathyroid hormone Proteins 0.000 claims description 17
229910052736 halogen Inorganic materials 0.000 claims description 17
150000002367 halogens Chemical class 0.000 claims description 17
210000002997 osteoclast Anatomy 0.000 claims description 17
OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims description 16
241000124008 Mammalia Species 0.000 claims description 16
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 16
239000001257 hydrogen Substances 0.000 claims description 16
229910052739 hydrogen Inorganic materials 0.000 claims description 16
102000005962 receptors Human genes 0.000 claims description 16
108020003175 receptors Proteins 0.000 claims description 16
230000002829 reductive effect Effects 0.000 claims description 16
229960001319 parathyroid hormone Drugs 0.000 claims description 15
239000008194 pharmaceutical composition Substances 0.000 claims description 15
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 14
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 13
230000002917 arthritic effect Effects 0.000 claims description 13
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
102000055006 Calcitonin Human genes 0.000 claims description 12
108060001064 Calcitonin Proteins 0.000 claims description 12
229960004015 calcitonin Drugs 0.000 claims description 12
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
102000008108 Osteoprotegerin Human genes 0.000 claims description 11
108010035042 Osteoprotegerin Proteins 0.000 claims description 11
239000002253 acid Substances 0.000 claims description 11
108010044426 integrins Proteins 0.000 claims description 11
102000006495 integrins Human genes 0.000 claims description 11
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 11
XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 claims description 11
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
229920006395 saturated elastomer Polymers 0.000 claims description 11
208000024891 symptom Diseases 0.000 claims description 11
229940062527 alendronate Drugs 0.000 claims description 10
125000004949 alkyl amino carbonyl amino group Chemical group 0.000 claims description 10
229910052799 carbon Inorganic materials 0.000 claims description 10
125000001153 fluoro group Chemical group F* 0.000 claims description 10
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims description 9
102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims description 9
125000006598 aminocarbonylamino group Chemical group 0.000 claims description 9
229940112869 bone morphogenetic protein Drugs 0.000 claims description 9
239000003937 drug carrier Substances 0.000 claims description 9
239000000583 progesterone congener Substances 0.000 claims description 9
238000001356 surgical procedure Methods 0.000 claims description 9
108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 8
230000009471 action Effects 0.000 claims description 8
230000008485 antagonism Effects 0.000 claims description 8
230000001833 anti-estrogenic effect Effects 0.000 claims description 8
230000027455 binding Effects 0.000 claims description 8
239000000328 estrogen antagonist Substances 0.000 claims description 8
239000000333 selective estrogen receptor modulator Substances 0.000 claims description 8
229940095743 selective estrogen receptor modulator Drugs 0.000 claims description 8
150000003721 vitamin K derivatives Chemical class 0.000 claims description 8
102000004171 Cathepsin K Human genes 0.000 claims description 7
108090000625 Cathepsin K Proteins 0.000 claims description 7
108090000854 Oxidoreductases Proteins 0.000 claims description 7
102000004316 Oxidoreductases Human genes 0.000 claims description 7
102000011731 Vacuolar Proton-Translocating ATPases Human genes 0.000 claims description 7
108010037026 Vacuolar Proton-Translocating ATPases Proteins 0.000 claims description 7
125000005196 alkyl carbonyloxy group Chemical group 0.000 claims description 7
229940046836 anti-estrogen Drugs 0.000 claims description 7
159000000007 calcium salts Chemical class 0.000 claims description 7
230000012010 growth Effects 0.000 claims description 7
230000004936 stimulating effect Effects 0.000 claims description 7
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 6
108010051696 Growth Hormone Proteins 0.000 claims description 6
RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 6
229930003448 Vitamin K Natural products 0.000 claims description 6
230000004913 activation Effects 0.000 claims description 6
125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 6
239000011575 calcium Substances 0.000 claims description 6
229910052791 calcium Inorganic materials 0.000 claims description 6
ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 claims description 6
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 6
239000000122 growth hormone Substances 0.000 claims description 6
125000005842 heteroatom Chemical group 0.000 claims description 6
230000001404 mediated effect Effects 0.000 claims description 6
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 6
150000003180 prostaglandins Chemical class 0.000 claims description 6
230000028327 secretion Effects 0.000 claims description 6
229960002855 simvastatin Drugs 0.000 claims description 6
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 6
235000019168 vitamin K Nutrition 0.000 claims description 6
239000011712 vitamin K Substances 0.000 claims description 6
229940046010 vitamin k Drugs 0.000 claims description 6
125000005871 1,3-benzodioxolyl group Chemical group 0.000 claims description 5
IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 claims description 5
229960002286 clodronic acid Drugs 0.000 claims description 5
GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 claims description 5
229940035811 conjugated estrogen Drugs 0.000 claims description 5
125000004093 cyano group Chemical group *C#N 0.000 claims description 5
235000005911 diet Nutrition 0.000 claims description 5
150000004673 fluoride salts Chemical class 0.000 claims description 5
125000002541 furyl group Chemical group 0.000 claims description 5
125000002883 imidazolyl group Chemical group 0.000 claims description 5
125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 5
125000001041 indolyl group Chemical group 0.000 claims description 5
125000005956 isoquinolyl group Chemical group 0.000 claims description 5
125000001786 isothiazolyl group Chemical group 0.000 claims description 5
125000000842 isoxazolyl group Chemical group 0.000 claims description 5
125000001715 oxadiazolyl group Chemical group 0.000 claims description 5
125000002971 oxazolyl group Chemical group 0.000 claims description 5
230000000858 peroxisomal effect Effects 0.000 claims description 5
229960002797 pitavastatin Drugs 0.000 claims description 5
125000003373 pyrazinyl group Chemical group 0.000 claims description 5
125000003226 pyrazolyl group Chemical group 0.000 claims description 5
125000004076 pyridyl group Chemical group 0.000 claims description 5
125000000714 pyrimidinyl group Chemical group 0.000 claims description 5
125000000168 pyrrolyl group Chemical group 0.000 claims description 5
125000005493 quinolyl group Chemical group 0.000 claims description 5
229940089617 risedronate Drugs 0.000 claims description 5
230000009759 skin aging Effects 0.000 claims description 5
PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 claims description 5
125000003831 tetrazolyl group Chemical group 0.000 claims description 5
125000001113 thiadiazolyl group Chemical group 0.000 claims description 5
125000000335 thiazolyl group Chemical group 0.000 claims description 5
125000001544 thienyl group Chemical group 0.000 claims description 5
125000001425 triazolyl group Chemical group 0.000 claims description 5
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
229940123613 Calcium receptor antagonist Drugs 0.000 claims description 4
DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 claims description 4
102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 4
108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 4
239000012826 P38 inhibitor Substances 0.000 claims description 4
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 4
239000012190 activator Substances 0.000 claims description 4
239000004480 active ingredient Substances 0.000 claims description 4
239000000362 adenosine triphosphatase inhibitor Substances 0.000 claims description 4
125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 4
150000003857 carboxamides Chemical class 0.000 claims description 4
125000000753 cycloalkyl group Chemical group 0.000 claims description 4
230000000378 dietary effect Effects 0.000 claims description 4
102000015694 estrogen receptors Human genes 0.000 claims description 4
108010038795 estrogen receptors Proteins 0.000 claims description 4
150000002431 hydrogen Chemical class 0.000 claims description 4
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 4
229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
235000010755 mineral Nutrition 0.000 claims description 4
239000011707 mineral Substances 0.000 claims description 4
201000008482 osteoarthritis Diseases 0.000 claims description 4
239000002464 receptor antagonist Substances 0.000 claims description 4
229940044551 receptor antagonist Drugs 0.000 claims description 4
CAKRAHQRJGUPIG-UHFFFAOYSA-M sodium;[4-azaniumyl-1-hydroxy-1-[hydroxy(oxido)phosphoryl]butyl]-hydroxyphosphinate Chemical group [Na+].NCCCC(O)(P(O)(O)=O)P(O)([O-])=O CAKRAHQRJGUPIG-UHFFFAOYSA-M 0.000 claims description 4
XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims description 4
229960004276 zoledronic acid Drugs 0.000 claims description 4
ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims description 3
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 3
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 3
MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 claims description 3
SFBODOKJTYAUCM-UHFFFAOYSA-N Ipriflavone Chemical compound C=1C(OC(C)C)=CC=C(C2=O)C=1OC=C2C1=CC=CC=C1 SFBODOKJTYAUCM-UHFFFAOYSA-N 0.000 claims description 3
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 3
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims description 3
DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 claims description 3
UGEPSJNLORCRBO-UHFFFAOYSA-N [3-(dimethylamino)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound CN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O UGEPSJNLORCRBO-UHFFFAOYSA-N 0.000 claims description 3
229960005370 atorvastatin Drugs 0.000 claims description 3
229960005110 cerivastatin Drugs 0.000 claims description 3
SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims description 3
229960003608 clomifene Drugs 0.000 claims description 3
125000004122 cyclic group Chemical group 0.000 claims description 3
229960002568 ethinylestradiol Drugs 0.000 claims description 3
229940009626 etidronate Drugs 0.000 claims description 3
229910052731 fluorine Inorganic materials 0.000 claims description 3
229960003765 fluvastatin Drugs 0.000 claims description 3
229940015872 ibandronate Drugs 0.000 claims description 3
230000001771 impaired effect Effects 0.000 claims description 3
229950006971 incadronic acid Drugs 0.000 claims description 3
229960005431 ipriflavone Drugs 0.000 claims description 3
229960004844 lovastatin Drugs 0.000 claims description 3
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 3
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 3
229960002985 medroxyprogesterone acetate Drugs 0.000 claims description 3
PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 claims description 3
VMMKGHQPQIEGSQ-UHFFFAOYSA-N minodronic acid Chemical compound C1=CC=CN2C(CC(O)(P(O)(O)=O)P(O)(O)=O)=CN=C21 VMMKGHQPQIEGSQ-UHFFFAOYSA-N 0.000 claims description 3
229950011129 minodronic acid Drugs 0.000 claims description 3
PUUSSSIBPPTKTP-UHFFFAOYSA-N neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 claims description 3
229950010733 neridronic acid Drugs 0.000 claims description 3
VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 claims description 3
WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims description 3
229940046231 pamidronate Drugs 0.000 claims description 3
RHGYHLPFVJEAOC-FFNUKLMVSA-L pitavastatin calcium Chemical compound [Ca+2].[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1.[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 RHGYHLPFVJEAOC-FFNUKLMVSA-L 0.000 claims description 3
229960002965 pravastatin Drugs 0.000 claims description 3
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims description 3
239000003909 protein kinase inhibitor Substances 0.000 claims description 3
229960004622 raloxifene Drugs 0.000 claims description 3
GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims description 3
206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
NTJHYIRSENEXDR-UHFFFAOYSA-M sodium;fluoro-dioxido-oxo-$l^{5}-phosphane;hydron Chemical compound [Na+].OP([O-])(F)=O NTJHYIRSENEXDR-UHFFFAOYSA-M 0.000 claims description 3
238000010254 subcutaneous injection Methods 0.000 claims description 3
239000007929 subcutaneous injection Substances 0.000 claims description 3
OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 claims description 3
229940019375 tiludronate Drugs 0.000 claims description 3
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 claims description 2
LHAPNDAERSFWSC-JGUILPGDSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;1-[2-[4-[(e)-1-(4-methoxyphenyl)-2-nitro-2-phenylethenyl]phenoxy]ethyl]pyrrolidine Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OC)=CC=C1C(\C=1C=CC(OCCN2CCCC2)=CC=1)=C([N+]([O-])=O)\C1=CC=CC=C1 LHAPNDAERSFWSC-JGUILPGDSA-N 0.000 claims description 2
STAHNFFHFRNPMD-OQKDUQJOSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;3-[4-[(z)-1-(4-methoxyphenyl)-2-nitro-2-phenylethenyl]phenoxy]-n,n-dimethylpropan-1-amine Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OC)=CC=C1C(\C=1C=CC(OCCCN(C)C)=CC=1)=C([N+]([O-])=O)/C1=CC=CC=C1 STAHNFFHFRNPMD-OQKDUQJOSA-N 0.000 claims description 2
101150061927 BMP2 gene Proteins 0.000 claims description 2
102000014914 Carrier Proteins Human genes 0.000 claims description 2
229940122156 Cathepsin K inhibitor Drugs 0.000 claims description 2
ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 claims description 2
241000283073 Equus caballus Species 0.000 claims description 2
DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 claims description 2
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 claims description 2
101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 claims description 2
JJKOTMDDZAJTGQ-DQSJHHFOSA-N Idoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN2CCCC2)=CC=1)/C1=CC=C(I)C=C1 JJKOTMDDZAJTGQ-DQSJHHFOSA-N 0.000 claims description 2
DTXXSJZBSTYZKE-ZDQKKZTESA-N Maxacalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](OCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C DTXXSJZBSTYZKE-ZDQKKZTESA-N 0.000 claims description 2
OEKMGABCSLYWOP-DHUJRADRSA-N [4-[(2s)-7-(2,2-dimethylpropanoyloxy)-4-methyl-2-[4-(2-piperidin-1-ylethoxy)phenyl]-2h-chromen-3-yl]phenyl] 2,2-dimethylpropanoate Chemical compound C1=CC([C@H]2C(=C(C3=CC=C(OC(=O)C(C)(C)C)C=C3O2)C)C=2C=CC(OC(=O)C(C)(C)C)=CC=2)=CC=C1OCCN1CCCCC1 OEKMGABCSLYWOP-DHUJRADRSA-N 0.000 claims description 2
DUYNJNWVGIWJRI-LJAQVGFWSA-N acolbifene Chemical compound C1=CC([C@H]2C(=C(C3=CC=C(O)C=C3O2)C)C=2C=CC(O)=CC=2)=CC=C1OCCN1CCCCC1 DUYNJNWVGIWJRI-LJAQVGFWSA-N 0.000 claims description 2
125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 2
108091008324 binding proteins Proteins 0.000 claims description 2
230000004097 bone metabolism Effects 0.000 claims description 2
LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 claims description 2
229960002882 calcipotriol Drugs 0.000 claims description 2
229960003773 calcitonin (salmon synthetic) Drugs 0.000 claims description 2
229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 2
239000001354 calcium citrate Substances 0.000 claims description 2
229940069978 calcium supplement Drugs 0.000 claims description 2
ILYCWAKSDCYMBB-OPCMSESCSA-N dihydrotachysterol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1/C[C@@H](O)CC[C@@H]1C ILYCWAKSDCYMBB-OPCMSESCSA-N 0.000 claims description 2
229960000465 dihydrotachysterol Drugs 0.000 claims description 2
229950004203 droloxifene Drugs 0.000 claims description 2
229960005309 estradiol Drugs 0.000 claims description 2
229960003399 estrone Drugs 0.000 claims description 2
239000011737 fluorine Substances 0.000 claims description 2
102000058004 human PTH Human genes 0.000 claims description 2
229950002248 idoxifene Drugs 0.000 claims description 2
229940043355 kinase inhibitor Drugs 0.000 claims description 2
GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 claims description 2
229960002367 lasofoxifene Drugs 0.000 claims description 2
XZEUAXYWNKYKPL-WDYNHAJCSA-N levormeloxifene Chemical compound C1([C@H]2[C@@H](C3=CC=C(C=C3OC2(C)C)OC)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 XZEUAXYWNKYKPL-WDYNHAJCSA-N 0.000 claims description 2
229950002728 levormeloxifene Drugs 0.000 claims description 2
239000003550 marker Substances 0.000 claims description 2
229950006319 maxacalcitol Drugs 0.000 claims description 2
229940097496 nasal spray Drugs 0.000 claims description 2
239000007922 nasal spray Substances 0.000 claims description 2
229960001652 norethindrone acetate Drugs 0.000 claims description 2
229960000672 rosuvastatin Drugs 0.000 claims description 2
BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims description 2
108010068072 salmon calcitonin Proteins 0.000 claims description 2
DUYCFMAOEDAKDN-UHFFFAOYSA-M sodium (4-amino-1-hydroxy-1-phosphonobutyl)-hydroxyphosphinate hydrate Chemical compound O.[Na+].NCCCC(O)(P(O)(O)=O)P(O)([O-])=O DUYCFMAOEDAKDN-UHFFFAOYSA-M 0.000 claims description 2
239000011775 sodium fluoride Substances 0.000 claims description 2
235000013024 sodium fluoride Nutrition 0.000 claims description 2
206010041569 spinal fracture Diseases 0.000 claims description 2
238000006467 substitution reaction Methods 0.000 claims description 2
229960001603 tamoxifen Drugs 0.000 claims description 2
235000013337 tricalcium citrate Nutrition 0.000 claims description 2
125000004390 alkyl sulfonyl group Chemical group 0.000 claims 4
102000014429 Insulin-like growth factor Human genes 0.000 claims 3
229940121819 ATPase inhibitor Drugs 0.000 claims 2
102000018997 Growth Hormone Human genes 0.000 claims 2
229940123934 Reductase inhibitor Drugs 0.000 claims 2
125000005602 azabenzimidazolyl group Chemical group 0.000 claims 2
230000009469 supplementation Effects 0.000 claims 2
QZLYKIGBANMMBK-UGCZWRCOSA-N 5α-Androstane Chemical compound C([C@@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CCC[C@@]2(C)CC1 QZLYKIGBANMMBK-UGCZWRCOSA-N 0.000 claims 1
101100042944 Arabidopsis thaliana SOB5 gene Proteins 0.000 claims 1
101150072730 Bmp6 gene Proteins 0.000 claims 1
101000764357 Homo sapiens Protein Tob1 Proteins 0.000 claims 1
102000002265 Human Growth Hormone Human genes 0.000 claims 1
108010000521 Human Growth Hormone Proteins 0.000 claims 1
239000000854 Human Growth Hormone Substances 0.000 claims 1
101100165554 Mus musculus Bmp5 gene Proteins 0.000 claims 1
101100165560 Mus musculus Bmp7 gene Proteins 0.000 claims 1
229940127473 Prostaglandin Receptor Agonists Drugs 0.000 claims 1
102000001253 Protein Kinase Human genes 0.000 claims 1
101100218949 Rattus norvegicus Bmp3 gene Proteins 0.000 claims 1
230000003213 activating effect Effects 0.000 claims 1
229940126864 fibroblast growth factor Drugs 0.000 claims 1
239000003862 glucocorticoid Substances 0.000 claims 1
229940088597 hormone Drugs 0.000 claims 1
239000005556 hormone Substances 0.000 claims 1
LWRDQHOZTAOILO-UHFFFAOYSA-N incadronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)NC1CCCCCC1 LWRDQHOZTAOILO-UHFFFAOYSA-N 0.000 claims 1
102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims 1
108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 claims 1
108060006633 protein kinase Proteins 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
229960005026 toremifene Drugs 0.000 claims 1
XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 claims 1
GKIRPKYJQBWNGO-QPLCGJKRSA-N zuclomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(/Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-QPLCGJKRSA-N 0.000 claims 1
229950010004 zuclomifene Drugs 0.000 claims 1
210000001519 tissue Anatomy 0.000 abstract description 52
239000000556 agonist Substances 0.000 abstract description 31
239000013543 active substance Substances 0.000 abstract description 9
206010003246 arthritis Diseases 0.000 abstract description 6
201000003617 glucocorticoid-induced osteoporosis Diseases 0.000 abstract description 5
230000002757 inflammatory effect Effects 0.000 abstract description 5
230000008439 repair process Effects 0.000 abstract description 5
230000001668 ameliorated effect Effects 0.000 abstract description 4
230000003042 antagnostic effect Effects 0.000 abstract description 4
208000029725 Metabolic bone disease Diseases 0.000 abstract description 3
206010049088 Osteopenia Diseases 0.000 abstract description 3
230000032683 aging Effects 0.000 abstract 1
238000002278 reconstructive surgery Methods 0.000 abstract 1
230000000694 effects Effects 0.000 description 36
210000004027 cell Anatomy 0.000 description 35
239000000243 solution Substances 0.000 description 33
235000002639 sodium chloride Nutrition 0.000 description 29
239000000849 selective androgen receptor modulator Substances 0.000 description 25
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
238000012360 testing method Methods 0.000 description 22
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
238000002360 preparation method Methods 0.000 description 20
239000007787 solid Substances 0.000 description 19
230000006870 function Effects 0.000 description 17
241000700159 Rattus Species 0.000 description 16
239000003446 ligand Substances 0.000 description 16
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
238000001819 mass spectrum Methods 0.000 description 14
229940030486 androgens Drugs 0.000 description 13
201000010099 disease Diseases 0.000 description 13
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
239000002617 bone density conservation agent Substances 0.000 description 12
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
230000002265 prevention Effects 0.000 description 12
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 11
238000011161 development Methods 0.000 description 11
230000018109 developmental process Effects 0.000 description 11
239000004615 ingredient Substances 0.000 description 11
102100026933 Myelin-associated neurite-outgrowth inhibitor Human genes 0.000 description 10
229940079593 drug Drugs 0.000 description 10
239000003814 drug Substances 0.000 description 10
230000004824 osteo-anabolic effect Effects 0.000 description 10
108090000623 proteins and genes Proteins 0.000 description 10
239000011541 reaction mixture Substances 0.000 description 10
208000006386 Bone Resorption Diseases 0.000 description 9
239000005089 Luciferase Substances 0.000 description 9
230000024279 bone resorption Effects 0.000 description 9
208000035475 disorder Diseases 0.000 description 9
239000000047 product Substances 0.000 description 9
239000000126 substance Substances 0.000 description 9
206010017076 Fracture Diseases 0.000 description 8
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
238000004458 analytical method Methods 0.000 description 8
239000007788 liquid Substances 0.000 description 8
159000000000 sodium salts Chemical class 0.000 description 8
229940078581 Bone resorption inhibitor Drugs 0.000 description 7
108020004414 DNA Proteins 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
239000000051 antiandrogen Substances 0.000 description 7
230000009286 beneficial effect Effects 0.000 description 7
238000011534 incubation Methods 0.000 description 7
229920000642 polymer Polymers 0.000 description 7
239000000725 suspension Substances 0.000 description 7
210000001550 testis Anatomy 0.000 description 7
238000002560 therapeutic procedure Methods 0.000 description 7
238000001890 transfection Methods 0.000 description 7
108060001084 Luciferase Proteins 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
206010047486 Virilism Diseases 0.000 description 6
230000001548 androgenic effect Effects 0.000 description 6
230000002280 anti-androgenic effect Effects 0.000 description 6
239000000872 buffer Substances 0.000 description 6
239000003153 chemical reaction reagent Substances 0.000 description 6
238000004587 chromatography analysis Methods 0.000 description 6
239000010949 copper Substances 0.000 description 6
MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 6
239000002609 medium Substances 0.000 description 6
230000004044 response Effects 0.000 description 6
238000003756 stirring Methods 0.000 description 6
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 5
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
229960004343 alendronic acid Drugs 0.000 description 5
208000007502 anemia Diseases 0.000 description 5
238000011888 autopsy Methods 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
239000003480 eluent Substances 0.000 description 5
235000019439 ethyl acetate Nutrition 0.000 description 5
230000003993 interaction Effects 0.000 description 5
150000002632 lipids Chemical class 0.000 description 5
235000018102 proteins Nutrition 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
210000001625 seminal vesicle Anatomy 0.000 description 5
239000000741 silica gel Substances 0.000 description 5
229910002027 silica gel Inorganic materials 0.000 description 5
239000002904 solvent Substances 0.000 description 5
239000003826 tablet Substances 0.000 description 5
210000000689 upper leg Anatomy 0.000 description 5
201000010653 vesiculitis Diseases 0.000 description 5
LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 4
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 4
102000005600 Cathepsins Human genes 0.000 description 4
108010084457 Cathepsins Proteins 0.000 description 4
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
229940127449 Integrin Receptor Antagonists Drugs 0.000 description 4
YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 4
102000013275 Somatomedins Human genes 0.000 description 4
102100038803 Somatotropin Human genes 0.000 description 4
229940123464 Thiazolidinedione Drugs 0.000 description 4
150000007513 acids Chemical class 0.000 description 4
230000008484 agonism Effects 0.000 description 4
150000001412 amines Chemical class 0.000 description 4
229960000997 bicalutamide Drugs 0.000 description 4
125000002619 bicyclic group Chemical group 0.000 description 4
238000001816 cooling Methods 0.000 description 4
230000001054 cortical effect Effects 0.000 description 4
230000034994 death Effects 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
230000009977 dual effect Effects 0.000 description 4
150000002148 esters Chemical class 0.000 description 4
229960002074 flutamide Drugs 0.000 description 4
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
239000012634 fragment Substances 0.000 description 4
108020001507 fusion proteins Proteins 0.000 description 4
102000037865 fusion proteins Human genes 0.000 description 4
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
229910000041 hydrogen chloride Inorganic materials 0.000 description 4
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 4
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
210000004379 membrane Anatomy 0.000 description 4
239000012528 membrane Substances 0.000 description 4
125000002950 monocyclic group Chemical group 0.000 description 4
231100000252 nontoxic Toxicity 0.000 description 4
230000003000 nontoxic effect Effects 0.000 description 4
HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 4
102000004196 processed proteins & peptides Human genes 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
230000009467 reduction Effects 0.000 description 4
239000012266 salt solution Substances 0.000 description 4
210000004706 scrotum Anatomy 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
239000004059 squalene synthase inhibitor Substances 0.000 description 4
238000007920 subcutaneous administration Methods 0.000 description 4
239000000829 suppository Substances 0.000 description 4
YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 4
150000001467 thiazolidinediones Chemical class 0.000 description 4
238000005406 washing Methods 0.000 description 4
239000008215 water for injection Substances 0.000 description 4
GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 3
CCCIJQPRIXGQOE-XWSJACJDSA-N 17beta-hydroxy-17-methylestra-4,9,11-trien-3-one Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C=C2 CCCIJQPRIXGQOE-XWSJACJDSA-N 0.000 description 3
108091006112 ATPases Proteins 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
102000057290 Adenosine Triphosphatases Human genes 0.000 description 3
208000020084 Bone disease Diseases 0.000 description 3
PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 3
108010022452 Collagen Type I Proteins 0.000 description 3
102000012422 Collagen Type I Human genes 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
206010020100 Hip fracture Diseases 0.000 description 3
208000033830 Hot Flashes Diseases 0.000 description 3
206010060800 Hot flush Diseases 0.000 description 3
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 3
206010061902 Pancreatic neoplasm Diseases 0.000 description 3
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
102000004142 Trypsin Human genes 0.000 description 3
108090000631 Trypsin Proteins 0.000 description 3
210000000579 abdominal fat Anatomy 0.000 description 3
239000003263 anabolic agent Substances 0.000 description 3
230000001195 anabolic effect Effects 0.000 description 3
238000009167 androgen deprivation therapy Methods 0.000 description 3
238000013459 approach Methods 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 3
238000001704 evaporation Methods 0.000 description 3
230000008020 evaporation Effects 0.000 description 3
239000000499 gel Substances 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
235000011187 glycerol Nutrition 0.000 description 3
210000004394 hip joint Anatomy 0.000 description 3
235000012907 honey Nutrition 0.000 description 3
238000002657 hormone replacement therapy Methods 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
239000000463 material Substances 0.000 description 3
229960001566 methyltestosterone Drugs 0.000 description 3
238000002156 mixing Methods 0.000 description 3
238000000465 moulding Methods 0.000 description 3
XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 3
229960002653 nilutamide Drugs 0.000 description 3
238000011474 orchiectomy Methods 0.000 description 3
201000002528 pancreatic cancer Diseases 0.000 description 3
208000008443 pancreatic carcinoma Diseases 0.000 description 3
230000037361 pathway Effects 0.000 description 3
PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
239000000843 powder Substances 0.000 description 3
238000009097 single-agent therapy Methods 0.000 description 3
229960003604 testosterone Drugs 0.000 description 3
238000012546 transfer Methods 0.000 description 3
239000012588 trypsin Substances 0.000 description 3
238000010396 two-hybrid screening Methods 0.000 description 3
LRFWYBZWRQWZIM-UHFFFAOYSA-N (2-fluorophenyl)methanamine Chemical compound NCC1=CC=CC=C1F LRFWYBZWRQWZIM-UHFFFAOYSA-N 0.000 description 2
NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
239000005541 ACE inhibitor Substances 0.000 description 2
244000215068 Acacia senegal Species 0.000 description 2
208000002874 Acne Vulgaris Diseases 0.000 description 2
102100030988 Angiotensin-converting enzyme Human genes 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
241000416162 Astragalus gummifer Species 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
206010065687 Bone loss Diseases 0.000 description 2
229940127291 Calcium channel antagonist Drugs 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
208000024172 Cardiovascular disease Diseases 0.000 description 2
RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
102000005927 Cysteine Proteases Human genes 0.000 description 2
108010005843 Cysteine Proteases Proteins 0.000 description 2
102000002045 Endothelin Human genes 0.000 description 2
108050009340 Endothelin Proteins 0.000 description 2
YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
229930182566 Gentamicin Natural products 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
102000003886 Glycoproteins Human genes 0.000 description 2
108090000288 Glycoproteins Proteins 0.000 description 2
102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 description 2
239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 2
229920000084 Gum arabic Polymers 0.000 description 2
101000976075 Homo sapiens Insulin Proteins 0.000 description 2
101000864104 Homo sapiens WD40 repeat-containing protein SMU1 Proteins 0.000 description 2
206010058359 Hypogonadism Diseases 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
102000007330 LDL Lipoproteins Human genes 0.000 description 2
108010007622 LDL Lipoproteins Proteins 0.000 description 2
102000000853 LDL receptors Human genes 0.000 description 2
108010001831 LDL receptors Proteins 0.000 description 2
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
102100030817 Liver carboxylesterase 1 Human genes 0.000 description 2
101710181187 Liver carboxylesterase 1 Proteins 0.000 description 2
241000282560 Macaca mulatta Species 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
108090000375 Mineralocorticoid Receptors Proteins 0.000 description 2
102100021316 Mineralocorticoid receptor Human genes 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
JKWKMORAXJQQSR-MOPIKTETSA-N Nandrolone Decanoate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCCCCC)[C@@]1(C)CC2 JKWKMORAXJQQSR-MOPIKTETSA-N 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
206010030247 Oestrogen deficiency Diseases 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
229920001710 Polyorthoester Polymers 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
208000004403 Prostatic Hyperplasia Diseases 0.000 description 2
108700008625 Reporter Genes Proteins 0.000 description 2
241000283984 Rodentia Species 0.000 description 2
229940083324 Selective androgen receptor modulator Drugs 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
101710142969 Somatoliberin Proteins 0.000 description 2
102000005782 Squalene Monooxygenase Human genes 0.000 description 2
108020003891 Squalene monooxygenase Proteins 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 2
229930003779 Vitamin B12 Natural products 0.000 description 2
102100029872 WD40 repeat-containing protein SMU1 Human genes 0.000 description 2
235000010489 acacia gum Nutrition 0.000 description 2
239000000205 acacia gum Substances 0.000 description 2
229960001138 acetylsalicylic acid Drugs 0.000 description 2
206010000496 acne Diseases 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
DCSBSVSZJRSITC-UHFFFAOYSA-M alendronate sodium trihydrate Chemical compound O.O.O.[Na+].NCCCC(O)(P(O)(O)=O)P(O)([O-])=O DCSBSVSZJRSITC-UHFFFAOYSA-M 0.000 description 2
150000001335 aliphatic alkanes Chemical class 0.000 description 2
125000003545 alkoxy group Chemical group 0.000 description 2
125000002877 alkyl aryl group Chemical group 0.000 description 2
125000001118 alkylidene group Chemical group 0.000 description 2
POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
229940070021 anabolic steroids Drugs 0.000 description 2
238000009165 androgen replacement therapy Methods 0.000 description 2
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
230000000123 anti-resoprtive effect Effects 0.000 description 2
229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 2
229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
230000003078 antioxidant effect Effects 0.000 description 2
235000006708 antioxidants Nutrition 0.000 description 2
125000003710 aryl alkyl group Chemical group 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000002876 beta blocker Substances 0.000 description 2
229940097320 beta blocking agent Drugs 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
239000003613 bile acid Substances 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
229920002988 biodegradable polymer Polymers 0.000 description 2
239000004621 biodegradable polymer Substances 0.000 description 2
229920001400 block copolymer Polymers 0.000 description 2
210000000601 blood cell Anatomy 0.000 description 2
210000001772 blood platelet Anatomy 0.000 description 2
230000010478 bone regeneration Effects 0.000 description 2
239000006172 buffering agent Substances 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
239000000480 calcium channel blocker Substances 0.000 description 2
235000011089 carbon dioxide Nutrition 0.000 description 2
238000012754 cardiac puncture Methods 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000003610 charcoal Substances 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
230000001906 cholesterol absorption Effects 0.000 description 2
AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
229940075614 colloidal silicon dioxide Drugs 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
238000010276 construction Methods 0.000 description 2
238000013267 controlled drug release Methods 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
239000006071 cream Substances 0.000 description 2
RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 2
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
ZZFKAZHZSSJSSE-UHFFFAOYSA-L disodium;[(cycloheptylamino)-[hydroxy(oxido)phosphoryl]methyl]-hydroxyphosphinate;hydrate Chemical compound O.[Na+].[Na+].OP(O)(=O)C(P([O-])([O-])=O)NC1CCCCCC1 ZZFKAZHZSSJSSE-UHFFFAOYSA-L 0.000 description 2
239000002270 dispersing agent Substances 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
230000029142 excretion Effects 0.000 description 2
208000016253 exhaustion Diseases 0.000 description 2
OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 2
229960000815 ezetimibe Drugs 0.000 description 2
230000001815 facial effect Effects 0.000 description 2
229960002297 fenofibrate Drugs 0.000 description 2
YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 2
229960000304 folic acid Drugs 0.000 description 2
235000019152 folic acid Nutrition 0.000 description 2
239000011724 folic acid Substances 0.000 description 2
210000004392 genitalia Anatomy 0.000 description 2
229960002518 gentamicin Drugs 0.000 description 2
239000008187 granular material Substances 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
210000001624 hip Anatomy 0.000 description 2
150000004677 hydrates Chemical class 0.000 description 2
239000000017 hydrogel Substances 0.000 description 2
YPQLFJODEKMJEF-UHFFFAOYSA-N hydroxyflutamide Chemical compound CC(C)(O)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 YPQLFJODEKMJEF-UHFFFAOYSA-N 0.000 description 2
229910052588 hydroxylapatite Inorganic materials 0.000 description 2
239000012535 impurity Substances 0.000 description 2
239000000411 inducer Substances 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
150000007529 inorganic bases Chemical class 0.000 description 2
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
210000001503 joint Anatomy 0.000 description 2
239000004310 lactic acid Substances 0.000 description 2
235000014655 lactic acid Nutrition 0.000 description 2
108020001756 ligand binding domains Proteins 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
230000037356 lipid metabolism Effects 0.000 description 2
229910052744 lithium Inorganic materials 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
238000004020 luminiscence type Methods 0.000 description 2
239000012139 lysis buffer Substances 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 2
229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 2
WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 description 2
PSNSVDSRLUYDKF-UHFFFAOYSA-N methyl benzenesulfinate Chemical compound COS(=O)C1=CC=CC=C1 PSNSVDSRLUYDKF-UHFFFAOYSA-N 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
230000003228 microsomal effect Effects 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
125000002757 morpholinyl group Chemical group 0.000 description 2
229960001935 nandrolone decanoate Drugs 0.000 description 2
229960003512 nicotinic acid Drugs 0.000 description 2
235000001968 nicotinic acid Nutrition 0.000 description 2
239000011664 nicotinic acid Substances 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
230000002611 ovarian Effects 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
229960003531 phenolsulfonphthalein Drugs 0.000 description 2
229960005095 pioglitazone Drugs 0.000 description 2
125000003386 piperidinyl group Chemical group 0.000 description 2
VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 2
229920001610 polycaprolactone Polymers 0.000 description 2
229920002721 polycyanoacrylate Polymers 0.000 description 2
229920000728 polyester Polymers 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229940113116 polyethylene glycol 1000 Drugs 0.000 description 2
229940057838 polyethylene glycol 4000 Drugs 0.000 description 2
229920006324 polyoxymethylene Polymers 0.000 description 2
229920001296 polysiloxane Polymers 0.000 description 2
239000004814 polyurethane Substances 0.000 description 2
239000011591 potassium Substances 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
230000002028 premature Effects 0.000 description 2
238000012545 processing Methods 0.000 description 2
ODLMAHJVESYWTB-UHFFFAOYSA-N propylbenzene Chemical compound CCCC1=CC=CC=C1 ODLMAHJVESYWTB-UHFFFAOYSA-N 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
239000000612 proton pump inhibitor Substances 0.000 description 2
229940126409 proton pump inhibitor Drugs 0.000 description 2
LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
125000000719 pyrrolidinyl group Chemical group 0.000 description 2
230000001850 reproductive effect Effects 0.000 description 2
238000011808 rodent model Methods 0.000 description 2
229960004586 rosiglitazone Drugs 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
PAYGMRRPBHYIMA-UHFFFAOYSA-N sodium;trihydrate Chemical compound O.O.O.[Na] PAYGMRRPBHYIMA-UHFFFAOYSA-N 0.000 description 2
235000003687 soy isoflavones Nutrition 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
230000001629 suppression Effects 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
239000006188 syrup Substances 0.000 description 2
229960004559 theobromine Drugs 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000004797 therapeutic response Effects 0.000 description 2
238000004809 thin layer chromatography Methods 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
150000003626 triacylglycerols Chemical class 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
229960001641 troglitazone Drugs 0.000 description 2
GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 2
GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 2
239000002691 unilamellar liposome Substances 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
230000001792 virilizing effect Effects 0.000 description 2
230000009278 visceral effect Effects 0.000 description 2
235000019163 vitamin B12 Nutrition 0.000 description 2
239000011715 vitamin B12 Substances 0.000 description 2
PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Polymers OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 1
UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
DQFQCHIDRBIESA-UHFFFAOYSA-N 1-benzazepine Chemical compound N1C=CC=CC2=CC=CC=C12 DQFQCHIDRBIESA-UHFFFAOYSA-N 0.000 description 1
SDTORDSXCYSNTD-UHFFFAOYSA-N 1-methoxy-4-[(4-methoxyphenyl)methoxymethyl]benzene Chemical compound C1=CC(OC)=CC=C1COCC1=CC=C(OC)C=C1 SDTORDSXCYSNTD-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
JNYAEWCLZODPBN-UHFFFAOYSA-N 2-(1,2-dihydroxyethyl)oxolane-3,4-diol Polymers OCC(O)C1OCC(O)C1O JNYAEWCLZODPBN-UHFFFAOYSA-N 0.000 description 1
VBLXCTYLWZJBKA-UHFFFAOYSA-N 2-(trifluoromethyl)aniline Chemical compound NC1=CC=CC=C1C(F)(F)F VBLXCTYLWZJBKA-UHFFFAOYSA-N 0.000 description 1
OIALIKXMLIAOSN-UHFFFAOYSA-N 2-Propylpyridine Chemical compound CCCC1=CC=CC=N1 OIALIKXMLIAOSN-UHFFFAOYSA-N 0.000 description 1
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
ADSOSINJPNKUJK-UHFFFAOYSA-N 2-butylpyridine Chemical compound CCCCC1=CC=CC=N1 ADSOSINJPNKUJK-UHFFFAOYSA-N 0.000 description 1
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
229940013085 2-diethylaminoethanol Drugs 0.000 description 1
NRGGMCIBEHEAIL-UHFFFAOYSA-N 2-ethylpyridine Chemical compound CCC1=CC=CC=N1 NRGGMCIBEHEAIL-UHFFFAOYSA-N 0.000 description 1
BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
JBQWQBSRIAGTJT-UHFFFAOYSA-N 3-ethylmorpholine Chemical compound CCC1COCCN1 JBQWQBSRIAGTJT-UHFFFAOYSA-N 0.000 description 1
YLUDSYGJHAQGOD-UHFFFAOYSA-N 3-ethylpiperidine Chemical compound CCC1CCCNC1 YLUDSYGJHAQGOD-UHFFFAOYSA-N 0.000 description 1
HEOQXHNKRXRCTO-UHFFFAOYSA-N 6,7,8,9-tetrahydro-5h-benzo[7]annulene Chemical compound C1CCCCC2=CC=CC=C21 HEOQXHNKRXRCTO-UHFFFAOYSA-N 0.000 description 1
BKBBHXQBVJMMHW-UHFFFAOYSA-N 6,7-dihydro-5h-dibenzo[2,1-b:2',1'-e][7]annulene Chemical compound C1CCC2=CC=CC=C2C2=CC=CC=C21 BKBBHXQBVJMMHW-UHFFFAOYSA-N 0.000 description 1
101150053132 ABCI1 gene Proteins 0.000 description 1
241000349731 Afzelia bipindensis Species 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
101001091423 Agaricus bisporus Polyphenol oxidase 2 Proteins 0.000 description 1
POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
229940123413 Angiotensin II antagonist Drugs 0.000 description 1
102400000344 Angiotensin-1 Human genes 0.000 description 1
101800000734 Angiotensin-1 Proteins 0.000 description 1
101000611523 Arabidopsis thaliana Protoporphyrinogen oxidase 2, chloroplastic/mitochondrial Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
101710142885 Arginine N-succinyltransferase Proteins 0.000 description 1
208000009137 Behcet syndrome Diseases 0.000 description 1
GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
206010006811 Bursitis Diseases 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
239000002083 C09CA01 - Losartan Substances 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
229940126062 Compound A Drugs 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
235000017788 Cydonia oblonga Nutrition 0.000 description 1
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
230000004568 DNA-binding Effects 0.000 description 1
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 1
108010061435 Enalapril Proteins 0.000 description 1
108010092408 Eosinophil Peroxidase Proteins 0.000 description 1
102000003951 Erythropoietin Human genes 0.000 description 1
102100031939 Erythropoietin Human genes 0.000 description 1
108090000394 Erythropoietin Proteins 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
102100030863 Eyes absent homolog 1 Human genes 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
208000001640 Fibromyalgia Diseases 0.000 description 1
206010016717 Fistula Diseases 0.000 description 1
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
102100033417 Glucocorticoid receptor Human genes 0.000 description 1
201000005569 Gout Diseases 0.000 description 1
208000024659 Hemostatic disease Diseases 0.000 description 1
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
206010020112 Hirsutism Diseases 0.000 description 1
101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 1
101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 description 1
101000589423 Homo sapiens Proapoptotic nucleolar protein 1 Proteins 0.000 description 1
101000798130 Homo sapiens Tumor necrosis factor receptor superfamily member 11B Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
208000015580 Increased body weight Diseases 0.000 description 1
208000004575 Infectious Arthritis Diseases 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
102100037852 Insulin-like growth factor I Human genes 0.000 description 1
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
208000003456 Juvenile Arthritis Diseases 0.000 description 1
206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
102000009151 Luteinizing Hormone Human genes 0.000 description 1
108010073521 Luteinizing Hormone Proteins 0.000 description 1
208000016604 Lyme disease Diseases 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
102000004137 Lysophosphatidic Acid Receptors Human genes 0.000 description 1
108090000642 Lysophosphatidic Acid Receptors Proteins 0.000 description 1
208000001826 Marfan syndrome Diseases 0.000 description 1
102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
101100049053 Mus musculus Vash1 gene Proteins 0.000 description 1
208000023178 Musculoskeletal disease Diseases 0.000 description 1
201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
201000002481 Myositis Diseases 0.000 description 1
KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
206010031243 Osteogenesis imperfecta Diseases 0.000 description 1
206010031264 Osteonecrosis Diseases 0.000 description 1
108010016731 PPAR gamma Proteins 0.000 description 1
241001079606 Paches Species 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
108010039918 Polylysine Proteins 0.000 description 1
208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
102100032331 Proapoptotic nucleolar protein 1 Human genes 0.000 description 1
102100025803 Progesterone receptor Human genes 0.000 description 1
102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
102000015433 Prostaglandin Receptors Human genes 0.000 description 1
108010050183 Prostaglandin Receptors Proteins 0.000 description 1
102000006270 Proton Pumps Human genes 0.000 description 1
108010083204 Proton Pumps Proteins 0.000 description 1
201000001263 Psoriatic Arthritis Diseases 0.000 description 1
208000036824 Psoriatic arthropathy Diseases 0.000 description 1
208000012322 Raynaud phenomenon Diseases 0.000 description 1
208000033464 Reiter syndrome Diseases 0.000 description 1
206010038468 Renal hypertrophy Diseases 0.000 description 1
108091027981 Response element Proteins 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
DRFDPXKCEWYIAW-UHFFFAOYSA-M Risedronate sodium Chemical group [Na+].OP(=O)(O)C(P(O)([O-])=O)(O)CC1=CC=CN=C1 DRFDPXKCEWYIAW-UHFFFAOYSA-M 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
208000021386 Sjogren Syndrome Diseases 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
LKAJKIOFIWVMDJ-IYRCEVNGSA-N Stanazolol Chemical compound C([C@@H]1CC[C@H]2[C@@H]3CC[C@@]([C@]3(CC[C@@H]2[C@@]1(C)C1)C)(O)C)C2=C1C=NN2 LKAJKIOFIWVMDJ-IYRCEVNGSA-N 0.000 description 1
208000002847 Surgical Wound Diseases 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
208000000491 Tendinopathy Diseases 0.000 description 1
206010043255 Tendonitis Diseases 0.000 description 1
108010049264 Teriparatide Proteins 0.000 description 1
208000026062 Tissue disease Diseases 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
206010062662 Uterine mass Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
229930003268 Vitamin C Natural products 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
PFRQBZFETXBLTP-UHFFFAOYSA-N Vitamin K2 Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-UHFFFAOYSA-N 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
XACUEDCHPANNRH-UHFFFAOYSA-L [Ag+2].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F Chemical compound [Ag+2].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F XACUEDCHPANNRH-UHFFFAOYSA-L 0.000 description 1
101150090313 abc1 gene Proteins 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
238000011360 adjunctive therapy Methods 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 1
150000001336 alkenes Chemical class 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
150000001345 alkine derivatives Chemical class 0.000 description 1
150000004703 alkoxides Chemical class 0.000 description 1
125000000304 alkynyl group Chemical group 0.000 description 1
OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
229960000458 allantoin Drugs 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
229940124325 anabolic agent Drugs 0.000 description 1
229960003473 androstanolone Drugs 0.000 description 1
239000002870 angiogenesis inducing agent Substances 0.000 description 1
ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
229940127218 antiplatelet drug Drugs 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
229960003121 arginine Drugs 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
230000000923 atherogenic effect Effects 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
238000010533 azeotropic distillation Methods 0.000 description 1
125000002393 azetidinyl group Chemical group 0.000 description 1
230000006399 behavior Effects 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
235000012216 bentonite Nutrition 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
RVSGRNKUJJUAPV-UHFFFAOYSA-N benzo[d][1,2]benzoxazepine Chemical compound O1N=CC2=CC=CC=C2C2=CC=CC=C12 RVSGRNKUJJUAPV-UHFFFAOYSA-N 0.000 description 1
229940049706 benzodiazepine Drugs 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
235000013734 beta-carotene Nutrition 0.000 description 1
239000011648 beta-carotene Substances 0.000 description 1
TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
229960002747 betacarotene Drugs 0.000 description 1
229960003237 betaine Drugs 0.000 description 1
QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
239000012148 binding buffer Substances 0.000 description 1
230000008033 biological extinction Effects 0.000 description 1
230000008512 biological response Effects 0.000 description 1
YKGYQYOQRGPFTO-UHFFFAOYSA-N bis(8-methylnonyl) hexanedioate Chemical compound CC(C)CCCCCCCOC(=O)CCCCC(=O)OCCCCCCCC(C)C YKGYQYOQRGPFTO-UHFFFAOYSA-N 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000037182 bone density Effects 0.000 description 1
230000008468 bone growth Effects 0.000 description 1
210000002798 bone marrow cell Anatomy 0.000 description 1
230000010072 bone remodeling Effects 0.000 description 1
108010009896 bone resorption factor Proteins 0.000 description 1
230000037118 bone strength Effects 0.000 description 1
239000012267 brine Substances 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
229960001948 caffeine Drugs 0.000 description 1
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
229960000830 captopril Drugs 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
229960000590 celecoxib Drugs 0.000 description 1
RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
238000000423 cell based assay Methods 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
210000003855 cell nucleus Anatomy 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
125000004803 chlorobenzyl group Chemical group 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
208000020832 chronic kidney disease Diseases 0.000 description 1
208000022831 chronic renal failure syndrome Diseases 0.000 description 1
239000012459 cleaning agent Substances 0.000 description 1
229960001214 clofibrate Drugs 0.000 description 1
KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
108010049937 collagen type I trimeric cross-linked peptide Proteins 0.000 description 1
229940096422 collagen type i Drugs 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
235000008504 concentrate Nutrition 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
238000007596 consolidation process Methods 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
238000011443 conventional therapy Methods 0.000 description 1
239000013256 coordination polymer Substances 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
229940111134 coxibs Drugs 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
235000000639 cyanocobalamin Nutrition 0.000 description 1
239000011666 cyanocobalamin Substances 0.000 description 1
229960002104 cyanocobalamin Drugs 0.000 description 1
WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000010586 diagram Methods 0.000 description 1
PJQCANLCUDUPRF-UHFFFAOYSA-N dibenzocycloheptene Chemical compound C1CC2=CC=CC=C2CC2=CC=CC=C12 PJQCANLCUDUPRF-UHFFFAOYSA-N 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
229960004166 diltiazem Drugs 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
230000035622 drinking Effects 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
229960000873 enalapril Drugs 0.000 description 1
238000003821 enantio-separation Methods 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
230000007368 endocrine function Effects 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
229940105423 erythropoietin Drugs 0.000 description 1
230000001076 estrogenic effect Effects 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
238000005562 fading Methods 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000000835 fiber Substances 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
239000002319 fibrinogen receptor antagonist Substances 0.000 description 1
230000003890 fistula Effects 0.000 description 1
229930003935 flavonoid Natural products 0.000 description 1
235000017173 flavonoids Nutrition 0.000 description 1
150000002215 flavonoids Chemical class 0.000 description 1
125000004175 fluorobenzyl group Chemical group 0.000 description 1
229940028334 follicle stimulating hormone Drugs 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
210000001061 forehead Anatomy 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000001640 fractional crystallisation Methods 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
239000012520 frozen sample Substances 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
229960003627 gemfibrozil Drugs 0.000 description 1
239000011521 glass Substances 0.000 description 1
229960002442 glucosamine Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
230000004153 glucose metabolism Effects 0.000 description 1
229960005150 glycerol Drugs 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
239000010931 gold Substances 0.000 description 1
235000013882 gravy Nutrition 0.000 description 1
230000003779 hair growth Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
102000044890 human EPO Human genes 0.000 description 1
102000052781 human TNFRSF11B Human genes 0.000 description 1
XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
KEBHLNDPKPIPLI-UHFFFAOYSA-N hydron;2-(3h-inden-4-yloxymethyl)morpholine;chloride Chemical compound Cl.C=1C=CC=2C=CCC=2C=1OCC1CNCCO1 KEBHLNDPKPIPLI-UHFFFAOYSA-N 0.000 description 1
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
239000005457 ice water Substances 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000007794 irritation Effects 0.000 description 1
229960002725 isoflurane Drugs 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
230000009916 joint effect Effects 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
201000008627 kidney hypertrophy Diseases 0.000 description 1
210000003127 knee Anatomy 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000002414 leg Anatomy 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000012280 lithium aluminium hydride Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000007774 longterm Effects 0.000 description 1
229960004773 losartan Drugs 0.000 description 1
KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
210000004705 lumbosacral region Anatomy 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
229940040129 luteinizing hormone Drugs 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000011572 manganese Substances 0.000 description 1
235000009491 menaquinone-4 Nutrition 0.000 description 1
239000011676 menaquinone-4 Substances 0.000 description 1
229960005481 menatetrenone Drugs 0.000 description 1
230000009245 menopause Effects 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000037323 metabolic rate Effects 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
239000007932 molded tablet Substances 0.000 description 1
MEFBJEMVZONFCJ-UHFFFAOYSA-N molybdate Chemical compound [O-][Mo]([O-])(=O)=O MEFBJEMVZONFCJ-UHFFFAOYSA-N 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
210000003098 myoblast Anatomy 0.000 description 1
229940078555 myristyl propionate Drugs 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229920001206 natural gum Polymers 0.000 description 1
230000030991 negative regulation of bone resorption Effects 0.000 description 1
229910052754 neon Inorganic materials 0.000 description 1
GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 1
208000018360 neuromuscular disease Diseases 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
229960001597 nifedipine Drugs 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
229940053934 norethindrone Drugs 0.000 description 1
108091008569 nuclear steroid hormone receptors Proteins 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
230000000474 nursing effect Effects 0.000 description 1
229960002378 oftasceine Drugs 0.000 description 1
238000009806 oophorectomy Methods 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
210000000963 osteoblast Anatomy 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
239000004031 partial agonist Substances 0.000 description 1
230000001991 pathophysiological effect Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
239000000816 peptidomimetic Substances 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
238000001050 pharmacotherapy Methods 0.000 description 1
125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
125000004344 phenylpropyl group Chemical group 0.000 description 1
150000008105 phosphatidylcholines Chemical class 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
239000003757 phosphotransferase inhibitor Substances 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
239000000106 platelet aggregation inhibitor Substances 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
229920000768 polyamine Polymers 0.000 description 1
201000010065 polycystic ovary syndrome Diseases 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920000151 polyglycol Polymers 0.000 description 1
239000010695 polyglycol Substances 0.000 description 1
229920000656 polylysine Polymers 0.000 description 1
229920000098 polyolefin Polymers 0.000 description 1
229940099429 polyoxyl 40 stearate Drugs 0.000 description 1
229920002635 polyurethane Polymers 0.000 description 1
229920002689 polyvinyl acetate Polymers 0.000 description 1
239000011118 polyvinyl acetate Substances 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
238000003825 pressing Methods 0.000 description 1
238000000899 pressurised-fluid extraction Methods 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
229960003912 probucol Drugs 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
108090000468 progesterone receptors Proteins 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
OSFBJERFMQCEQY-UHFFFAOYSA-N propylidene Chemical group [CH]CC OSFBJERFMQCEQY-UHFFFAOYSA-N 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
208000017497 prostate disease Diseases 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
150000003212 purines Chemical class 0.000 description 1
235000008160 pyridoxine Nutrition 0.000 description 1
239000011677 pyridoxine Substances 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
208000002574 reactive arthritis Diseases 0.000 description 1
230000030541 receptor transactivation Effects 0.000 description 1
239000006215 rectal suppository Substances 0.000 description 1
230000011514 reflex Effects 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
229960000371 rofecoxib Drugs 0.000 description 1
RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
238000010079 rubber tapping Methods 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
210000004761 scalp Anatomy 0.000 description 1
238000012216 screening Methods 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
201000001223 septic arthritis Diseases 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
239000002453 shampoo Substances 0.000 description 1
229920005573 silicon-containing polymer Polymers 0.000 description 1
235000015424 sodium Nutrition 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000011684 sodium molybdate Substances 0.000 description 1
235000015393 sodium molybdate Nutrition 0.000 description 1
TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 1
RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
JNYAEWCLZODPBN-CTQIIAAMSA-N sorbitan Polymers OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 description 1
208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
229960000912 stanozolol Drugs 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000005728 strengthening Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
125000004434 sulfur atom Chemical group 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
210000002820 sympathetic nervous system Anatomy 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
235000013616 tea Nutrition 0.000 description 1
201000004415 tendinitis Diseases 0.000 description 1
229960005460 teriparatide Drugs 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
229940063296 testosterone and estrogen Drugs 0.000 description 1
YRZGMTHQPGNLEK-UHFFFAOYSA-N tetradecyl propionate Chemical compound CCCCCCCCCCCCCCOC(=O)CC YRZGMTHQPGNLEK-UHFFFAOYSA-N 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
238000010257 thawing Methods 0.000 description 1
125000005301 thienylmethyl group Chemical group [H]C1=C([H])C([H])=C(S1)C([H])([H])* 0.000 description 1
108090000721 thyroid hormone receptors Proteins 0.000 description 1
102000004217 thyroid hormone receptors Human genes 0.000 description 1
210000002303 tibia Anatomy 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
230000037426 transcriptional repression Effects 0.000 description 1
239000012096 transfection reagent Substances 0.000 description 1
238000013519 translation Methods 0.000 description 1
230000005945 translocation Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
150000004684 trihydrates Chemical class 0.000 description 1
YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
229960000281 trometamol Drugs 0.000 description 1
102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
239000006216 vaginal suppository Substances 0.000 description 1
210000001177 vas deferen Anatomy 0.000 description 1
230000001457 vasomotor Effects 0.000 description 1
235000019155 vitamin A Nutrition 0.000 description 1
239000011719 vitamin A Substances 0.000 description 1
235000019154 vitamin C Nutrition 0.000 description 1
239000011718 vitamin C Substances 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
235000019143 vitamin K2 Nutrition 0.000 description 1
239000011728 vitamin K2 Substances 0.000 description 1
229940045997 vitamin a Drugs 0.000 description 1
229940011671 vitamin b6 Drugs 0.000 description 1
210000001260 vocal cord Anatomy 0.000 description 1
239000011534 wash buffer Substances 0.000 description 1
239000001993 wax Substances 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
208000016261 weight loss Diseases 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
210000000707 wrist Anatomy 0.000 description 1
239000000230 xanthan gum Substances 0.000 description 1
235000010493 xanthan gum Nutrition 0.000 description 1
229920001285 xanthan gum Polymers 0.000 description 1
229940082509 xanthan gum Drugs 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
229930195724 β-lactose Natural products 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
- C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
- C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Hematology (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Reproductive Health (AREA)
Obesity (AREA)
Virology (AREA)
Urology & Nephrology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Child & Adolescent Psychology (AREA)
Nutrition Science (AREA)
Oncology (AREA)
Cardiology (AREA)
Gynecology & Obstetrics (AREA)
Tropical Medicine & Parasitology (AREA)
Dermatology (AREA)

UA20041008266A 2002-03-13 2003-07-03 Fluorinated derivatives of 4-azasteroid as modulators of androgen receptor UA78029C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US36382202P	2002-03-13	2002-03-13
PCT/US2003/008277 WO2003077919A1 (en)	2002-03-13	2003-03-07	Fluorinated 4-azasteroid derivatives as androgen receptor modulators

Publications (1)

Publication Number	Publication Date
UA78029C2 true UA78029C2 (en)	2007-02-15

Family

ID=28041817

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA20041008266A UA78029C2 (en)	2002-03-13	2003-07-03	Fluorinated derivatives of 4-azasteroid as modulators of androgen receptor

Country Status (21)

Country	Link
US (1)	US7186838B2 (is)
EP (1)	EP1485095A4 (is)
JP (2)	JP4516316B2 (is)
KR (1)	KR100938136B1 (is)
CN (1)	CN1652786A (is)
AU (1)	AU2003218235B2 (is)
BR (1)	BR0308355A (is)
CA (1)	CA2478186C (is)
EC (1)	ECSP045287A (is)
HR (1)	HRP20040822A2 (is)
IL (2)	IL163825A0 (is)
IS (1)	IS7425A (is)
MA (1)	MA27112A1 (is)
MX (1)	MXPA04008800A (is)
NO (1)	NO20044312L (is)
NZ (1)	NZ534946A (is)
PL (1)	PL372920A1 (is)
RU (1)	RU2320670C2 (is)
UA (1)	UA78029C2 (is)
WO (1)	WO2003077919A1 (is)
ZA (1)	ZA200406843B (is)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7622503B2 (en)	2000-08-24	2009-11-24	University Of Tennessee Research Foundation	Selective androgen receptor modulators and methods of use thereof
US8853266B2 (en)	2001-12-06	2014-10-07	University Of Tennessee Research Foundation	Selective androgen receptor modulators for treating diabetes
US7772433B2 (en)	2002-02-28	2010-08-10	University Of Tennessee Research Foundation	SARMS and method of use thereof
KR100938136B1 (ko) *	2002-03-13	2010-01-22	머크 앤드 캄파니 인코포레이티드	안드로겐 수용체 조정자로서의 불화된 4-아자스테로이드 유도체 및 이를 포함하는 약제학적 조성물
KR20140021045A (ko) *	2002-05-10	2014-02-19	에프. 호프만-라 로슈 아게	골다공증 치료 및 예방용 비스포스폰산
US8309603B2 (en)	2004-06-07	2012-11-13	University Of Tennessee Research Foundation	SARMs and method of use thereof
US20070088042A1 (en) *	2004-09-09	2007-04-19	Meissner Robert S	Fluorinated 4-azasteroid derivatives as androgen receptor modulators
CN1849120A (zh) *	2003-09-10	2006-10-18	默克公司	作为雄激素受体调节剂的17－杂环－4－氮杂甾类衍生物
JP2007508386A (ja) *	2003-10-14	2007-04-05	ジーティーエックス・インコーポレイテッド	選択的アンドロゲン受容体調節剤による骨関連疾患の治療
CN1871005B (zh) *	2003-10-31	2010-10-27	默沙东公司	雄激素受体调节剂21-杂环-4-氮杂甾体衍生物
CA2551737C (en) *	2004-01-07	2009-11-10	Endorecherche, Inc.	Helix 12 directed steroidal pharmaceutical products
US20080125403A1 (en)	2004-04-02	2008-05-29	Merck & Co., Inc.	Method of Treating Men with Metabolic and Anthropometric Disorders
EP1742631A4 (en) *	2004-04-28	2009-11-11	Merck & Co Inc	FLUORATED 4-AZASTEROIDS AS ANDROGEN RECEPTOR MODULATORS
US9889110B2 (en)	2004-06-07	2018-02-13	University Of Tennessee Research Foundation	Selective androgen receptor modulator for treating hormone-related conditions
US9884038B2 (en)	2004-06-07	2018-02-06	University Of Tennessee Research Foundation	Selective androgen receptor modulator and methods of use thereof
JP2008510811A (ja) *	2004-08-25	2008-04-10	メルクエンドカムパニーインコーポレーテッド	アンドロゲン受容体モジュレーター
US20090123571A1 (en) *	2005-03-25	2009-05-14	Alan Meehan	Method of treating men with testosterone supplement and 5alpha-reductase inhibitor
US7301026B2 (en) *	2005-05-05	2007-11-27	Merck & Co., Inc	Process for making fluorinated 4-azasteroid derivatives
TW200730505A (en) *	2005-12-07	2007-08-16	Merck & Co Inc	Polymorphs of an androgen receptor modulator
US9730908B2 (en)	2006-08-24	2017-08-15	University Of Tennessee Research Foundation	SARMs and method of use thereof
US10010521B2 (en)	2006-08-24	2018-07-03	University Of Tennessee Research Foundation	SARMs and method of use thereof
US9844528B2 (en)	2006-08-24	2017-12-19	University Of Tennessee Research Foundation	SARMs and method of use thereof
JP5271272B2 (ja)	2006-11-16	2013-08-21	ジェンムスファーマインコーポレイティド	Ａ型インフルエンザウィルス感染の治療のための薬剤としてのｅｐ２およびｅｐ４作動薬
US7968603B2 (en)	2007-09-11	2011-06-28	University Of Tennessee Research Foundation	Solid forms of selective androgen receptor modulators
JP5539221B2 (ja)	2007-12-21	2014-07-02	リガンド・ファーマシューティカルズ・インコーポレイテッド	選択的アンドロゲン受容体モジュレーター（ｓａｒｍ）およびその使用
CN101990541A (zh) *	2008-02-07	2011-03-23	百时美施贵宝公司	糖皮质激素受体、AP-1和/或NF-κB活性的稠合杂芳基调节剂及其用途
EP2149551A1 (de)	2008-07-30	2010-02-03	Bayer Schering Pharma AG	N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors
EP2149554A1 (de)	2008-07-30	2010-02-03	Bayer Schering Pharma Aktiengesellschaft	Indolylamide als Modulatoren des EP2-Rezeptors
EP2149552A1 (de)	2008-07-30	2010-02-03	Bayer Schering Pharma AG	5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors
HUE033581T2 (hu)	2010-06-10	2017-12-28	Seragon Pharmaceuticals Inc	Ösztrogén receptor modulátorok és alkalmazásaik
DE102010027016A1 (de)	2010-07-09	2012-01-12	Universitätsklinikum Jena	Steroid-Styrylfarbstoff-Konjugate zur Simulation und direkten lichtoptischen Detektion des Verhaltens von Steroiden im lebenden biologischen Gewebe und in Gegenwart von steroidbindenden Proteinen
SG11201403002RA (en)	2011-12-14	2014-07-30	Seragon Pharmaceuticals Inc	Fluorinated estrogen receptor modulators and uses thereof
US10258596B2 (en)	2012-07-13	2019-04-16	Gtx, Inc.	Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9622992B2 (en)	2012-07-13	2017-04-18	Gtx, Inc.	Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9744149B2 (en)	2012-07-13	2017-08-29	Gtx, Inc.	Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10314807B2 (en)	2012-07-13	2019-06-11	Gtx, Inc.	Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
HUE052574T2 (hu)	2012-07-13	2021-05-28	Oncternal Therapeutics Inc	Eljárás mellrákok kezelésére szelektív ösztrogén receptor modulátorral (SARM)
US10987334B2 (en)	2012-07-13	2021-04-27	University Of Tennessee Research Foundation	Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US9969683B2 (en)	2012-07-13	2018-05-15	Gtx, Inc.	Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US9566310B2 (en)	2012-09-10	2017-02-14	Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Reno	Methods of treating muscular dystrophy
JP2016516051A (ja)	2013-03-15	2016-06-02	ボードオブリージェンツオブザネヴァダシステムオブハイヤーエデュケーションオンビハーフオブザユニヴァーシティーオブネヴァダリノ	筋ジストロフィーを治療する方法
WO2015108988A2 (en)	2014-01-17	2015-07-23	Ligand Pharmaceuticals, Inc.	Methods and compositions for modulating hormone levels
KR101586345B1 (ko) *	2014-08-06	2016-01-18	한국생명공학연구원	에스트라디올 벤조에이트(Estradiol benzoate) 또는 이의 약학적으로 허용 가능한 염을 포함하는 근력약화 관련 질환의 예방 또는 치료용 약학적 조성물
WO2019071144A1 (en)	2017-10-05	2019-04-11	Fulcrum Therapeutics, Inc.	USE OF P38 INHIBITORS TO REDUCE DUX4 EXPRESSION
US10342786B2 (en)	2017-10-05	2019-07-09	Fulcrum Therapeutics, Inc.	P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
KR102917075B1 (ko)	2018-02-11	2026-01-26	장쑤 한서 파마슈티칼 그룹 캄파니 리미티드	스테로이드 유도체 조절제, 그의 제조 방법 및 그의 용도
KR20220003554A (ko)	2019-04-19	2022-01-10	리간드 파마슈티칼스 인코포레이티드	화합물의 결정질 형태 및 결정질 형태를 제조하는 방법
US12624015B2 (en)	2019-06-24	2026-05-12	University Of Iowa Research Foundation	JNK inhibitors as anticancer agents
EP4011897A4 (en)	2019-08-07	2024-02-21	Shanghai Hansoh Biomedical Co., Ltd.	SALT AND CRYSTAL FORM OF A STEROID DERIVATIVE REGULATOR
US11904006B2 (en)	2019-12-11	2024-02-20	University Of Iowa Research Foundation	Poly(diaminosulfide) particle-based vaccine
CN112851745B (zh) *	2021-01-25	2021-11-16	广西民族大学	氮杂甾体吡啶类化合物及其合成与应用
US20240293322A1 (en)	2021-06-23	2024-09-05	University Of Iowa Research Foundation	Sustained release formulations comprising a selective androgen receptor modulator
CN115558013B (zh) *	2021-07-02	2025-02-18	石家庄迪斯凯威医药科技有限公司	一种甾体磷酸酯化合物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5187278A (en) *	1990-08-27	1993-02-16	Merck & Co., Inc.	Trialkylsilyl trifluoromethanesulfonate mediated α-methylenic carbon functionalization of 4-aza-5α-androstan-3-one steroids
IE76452B1 (en) *	1990-10-29	1997-10-22	Sankyo Co	Azasteroid compounds for the treatment of prostatic hypertrophy their preparation and use
GB9216284D0 (en) *	1992-07-31	1992-09-16	Erba Carlo Spa	Fluorinated 17beta-substituted 4-aza-5alpha-androstane-3-one derivatives
TW408127B (en) *	1993-09-17	2000-10-11	Glaxo Inc	Androstenones
AU707324B2 (en) *	1995-09-15	1999-07-08	Merck & Co., Inc.	4-azasteroids for treatment of hyperandrogenic conditions
AU5594398A (en) *	1996-12-09	1998-07-03	Merck & Co., Inc.	Methods and compositions for preventing and treating bone loss
KR100938136B1 (ko) *	2002-03-13	2010-01-22	머크 앤드 캄파니 인코포레이티드	안드로겐 수용체 조정자로서의 불화된 4-아자스테로이드 유도체 및 이를 포함하는 약제학적 조성물

2003
- 2003-03-07 KR KR1020047014281A patent/KR100938136B1/ko not_active Expired - Fee Related
- 2003-03-07 CA CA2478186A patent/CA2478186C/en not_active Expired - Fee Related
- 2003-03-07 JP JP2003575972A patent/JP4516316B2/ja not_active Expired - Fee Related
- 2003-03-07 RU RU2004130452/04A patent/RU2320670C2/ru not_active IP Right Cessation
- 2003-03-07 MX MXPA04008800A patent/MXPA04008800A/es active IP Right Grant
- 2003-03-07 HR HR20040822A patent/HRP20040822A2/hr not_active Application Discontinuation
- 2003-03-07 BR BR0308355-1A patent/BR0308355A/pt not_active IP Right Cessation
- 2003-03-07 NZ NZ534946A patent/NZ534946A/en not_active IP Right Cessation
- 2003-03-07 CN CNA038104857A patent/CN1652786A/zh active Pending
- 2003-03-07 AU AU2003218235A patent/AU2003218235B2/en not_active Ceased
- 2003-03-07 IL IL16382503A patent/IL163825A0/xx unknown
- 2003-03-07 PL PL03372920A patent/PL372920A1/xx not_active Application Discontinuation
- 2003-03-07 EP EP03714228A patent/EP1485095A4/en not_active Withdrawn
- 2003-03-07 US US10/507,239 patent/US7186838B2/en not_active Expired - Fee Related
- 2003-03-07 WO PCT/US2003/008277 patent/WO2003077919A1/en not_active Ceased
- 2003-07-03 UA UA20041008266A patent/UA78029C2/uk unknown
2004
- 2004-08-26 IS IS7425A patent/IS7425A/is unknown
- 2004-08-27 ZA ZA200406843A patent/ZA200406843B/en unknown
- 2004-08-31 IL IL163825A patent/IL163825A/en not_active IP Right Cessation
- 2004-09-10 EC EC2004005287A patent/ECSP045287A/es unknown
- 2004-10-07 MA MA27893A patent/MA27112A1/fr unknown
- 2004-10-12 NO NO20044312A patent/NO20044312L/no unknown
2010
- 2010-03-12 JP JP2010055367A patent/JP5268975B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
MA27112A1 (fr)	2004-12-20
ZA200406843B (en)	2007-06-27
US7186838B2 (en)	2007-03-06
RU2004130452A (ru)	2005-04-10
AU2003218235B2 (en)	2008-05-15
PL372920A1 (en)	2005-08-08
KR20040097167A (ko)	2004-11-17
US20050165039A1 (en)	2005-07-28
NZ534946A (en)	2007-05-31
AU2003218235A1 (en)	2003-09-29
IL163825A0 (en)	2005-12-18
ECSP045287A (es)	2004-10-26
HRP20040822A2 (en)	2005-06-30
IL163825A (en)	2010-12-30
EP1485095A1 (en)	2004-12-15
CA2478186C (en)	2011-08-23
NO20044312L (no)	2004-10-12
BR0308355A (pt)	2005-01-25
WO2003077919A1 (en)	2003-09-25
JP2010168391A (ja)	2010-08-05
CN1652786A (zh)	2005-08-10
RU2320670C2 (ru)	2008-03-27
IS7425A (is)	2004-08-26
JP5268975B2 (ja)	2013-08-21
JP2005526082A (ja)	2005-09-02
EP1485095A4 (en)	2009-11-18
JP4516316B2 (ja)	2010-08-04
CA2478186A1 (en)	2003-09-25
MXPA04008800A (es)	2004-11-26
KR100938136B1 (ko)	2010-01-22

Publication	Publication Date	Title
RU2320670C2 (ru)	2008-03-27	Фторированные производные 4-азастероида в качестве модуляторов рецептора андрогена
RU2378255C2 (ru)	2010-01-10	N-(2-бензил)-2-фенилбутанамиды в качестве модуляторов рецептора андрогена
AU2002330031B2 (en)	2007-07-05	Androstanes as androgen receptor modulators
EP1420796A1 (en)	2004-05-26	Androgen receptor modulators and methods of use thereof
JP2005529897A (ja)	2005-10-06	アンドロゲン受容体修飾因子としての４−アザステロイド誘導体
AU2002330031A1 (en)	2003-06-26	Androstanes as androgen receptor modulators
ES2291507T3 (es)	2008-03-01	Moduladores de receptor de androgenos y procedimientos de uso de los mismos.
AU2002340256A1 (en)	2003-07-03	Androgen receptor modulators and methods of use thereof
JP4490689B2 (ja)	2010-06-30	アンドロゲン受容体調節剤としてのアンドロスタン１７β−カルボキサミド類
AU2002331916A1 (en)	2003-06-26	Androstane 17-beta-carboxamides as androgen receptor modulators
JP4563032B2 (ja)	2010-10-13	アンドロゲン受容体モジュレータとしての１７−ヒドロキシ−４−アザ−アンドロスタン−３−オン
JP2007534757A (ja)	2007-11-29	アンドロゲン受容体モジュレーターとしてのフッ素付加４−アザステロイド
US7625920B2 (en)	2009-12-01	Fluorinated 4-azasteroid derivatives as androgen receptor modulators
AU2002322678B2 (en)	2007-03-08	Androgens receptor modulators and methods of use thereof
AU2002322678A1 (en)	2003-05-29	Androgens receptor modulators and methods of use thereof